VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase, following the completion of its collaboration with OmniAb. The company now plans to engineer the final candidate using its proprietary antibody-engineering, linker and conjugation technologies, and to conduct in vitro and in vivo preclinical studies. This progression signals a critical step toward clinical development for a novel therapeutic that could offer improved selectivity in cancer treatment.
VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells while sparing healthy tissue. This dual-targeting approach is part of VERAXA’s broader oncology pipeline, which spans ADCs, T-cell engagers and other engineered antibody formats. The company’s focus on next-generation antibody-based therapeutics positions it in a competitive landscape where precision and efficacy are paramount.
In addition to the VXA-222 milestone, VERAXA has filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms and related payload, click-chemistry and conjugation technologies. These filings add to an intellectual-property portfolio that already includes more than 50 granted patents across 26 families in 14 countries. Such robust IP protection is essential for securing a competitive advantage and attracting potential partners or investors in the biotech sector.
The advancement of VXA-222 and the expansion of VERAXA’s patent estate underscore the company’s commitment to innovation in antibody therapeutics. By leveraging technologies originally developed at the European Molecular Biology Laboratory, VERAXA aims to rapidly move its pipeline into clinical development and beyond. For investors and industry observers, this news highlights the company’s progress in a high-risk, high-reward field where successful candidates can address significant unmet medical needs.
To view the full article, visit https://ibn.fm/S3tyP. For regular updates about VERAXA Biotech, visit www.VERAXA.com. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
